TMCnet News
Nanovi Secures €2.7M to Market BioXmark and Expands Board of Directors [Global Data Point](Global Data Point Via Acquire Media NewsEdge) BioXmark™ is a novel injectable liquid tissue marker which improves the accuracy and quality of radiation therapy. It can easily be implemented in today's routines and equipment and will be available for commercial use in Europe during the first half of 2015. A high contrast marker being available for pre-treatment planning and image-guided radiotherapy is still a huge obstacle for getting the best result from radiotherapy. BioXmark™ forms a large 3D semi-solid gel and thus produces a high contrast visible with all commonly used high-precision imaging techniques including 2D/3D X-ray imaging (Fluoroscopy, ExacTrac, Cone Beam, and CT), MR and Ultrasound imaging. With about one million radiotherapy procedures using markers performed worldwide each year and a growing incidence of cancer, Nanovi's new technology targets a market exceeding EUR 10 billion. Jesper Roested, Investment Director, Vækstfonden says: "We are very pleased to see Nanovi progress in bringing BioXmark™ to the market, and we look forward to continue our close collaboration to help transforming Nanovi to a commercial company." Nanovi moreover brings two new board members to the company: Flemming Thorup, President and CEO of 3Shape A/S since 2001, who will serve as the Chairman of the Board of Directors, and Gordon McVie, MD, professor and an international authority on the treatment and research of cancer who will serve as a member of the Board of Directors. Morten Albrechtsen, CEO and co-founder of Nanovi says: "We are happy to welcome two new board members. Flemming Thorup brings distinctive skills on how to successfully commercialize and grow a medical company internationally, and Gordon McVie brings unmatched clinical understanding essential for successful commercialization of BioXmark™. We are also very pleased for the continued support and good collaboration with our investors, which keep our plan on-track and enables us to bring BioXmark™ to the marked already next year." (c) 2014 GlobalData Provided by SyndiGate Media Inc. (Syndigate.info). |